Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported a 12.9% increase in revenues to NOK 138.9 million in the third quarter of 2025.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, compared to NOK 8.6 million in 2024.
- Revenues: NOK 138.9 million, a 12.9% increase from Q3 2024
- Gross margin: 37.5%, compared to 37.1% in Q3 2024
- Adjusted EBITDA: NOK 11.3 million, compared to NOK 8.6 million in 2024
The revenue growth was driven by increases in all three business areas, including the Rx business area, which included NOK 10.6 million in revenues from the dne business.
No direct quote available in the text.
Author's summary: Navamedic ASA reports 12.9% revenue growth.
More News
- [Commissioner Dexter McCoy launches bid for Fort Bend County judge, citing need for new leadership]
- Why Redwire Stock Collapsed 30% Last Month
- [collapsed adjective - Definition, pictures, pronunciation and ...]
- Playback: The Law discussed Daddy Lumba’s case
- Tour news: Rosalía, Taskmaster, Don Letts & Daddy G, De La Soul, LCD Soundsystem, Amyl & The Sniffers, Lily Allen, more
- Read Customer Service Reviews of charlies.co.uk
- Rapala x Charlie's Fishing Limited Edition Super Shadow Rap Glide 11
- Bills great calls out Brandon Beane for failing Josh Allen
- Charlie's Holdings Announces Opening of US Manufacturing Facility and First Shipments to Texas Customers
- Great Smoky Mountains National Park: Charlies Bunion Loop